Industry News
Pharmaceutical Industry News
The sudden departure of Vinay…
The sudden departure of Vinay Prasad, M.D., from the FDA again threw the cell and gene therapy field into uncertainty. But this time, the unknown is hitting the industry in a different way from when
Eli Lilly has presented phase 3…
Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease. While Lilly called it a
The first commercial for Johnson…
The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple myeloma patient’s life, both before and after treatment with the CAR-T therapy.
As Celltrion looks to ward off…
As Celltrion looks to ward off potential import tariffs, the South Korean company’s odds at acquiring a large-scale drug substance plant in the U.S. have gone up considerably.
Following the departure of Vinay…
Following the departure of Vinay Prasad, M.D., former head of the Center for Biologics Evaluation and Research, the FDA has already tapped someone else to temporarily fill his shoes.
The Japanese drugmaker’s quarterly…
The Japanese drugmaker's quarterly revenues took an 8.4% hit with continued Vyvanse-related generic erosion reaching a high and bringing down its U.S. sales.
With a portfolio of 14 potential…
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ($53
With rates of colorectal cancer…
With rates of colorectal cancer surging among younger populations, Guardant Health is turning to a famous face beloved by Gen X and millennials to raise awareness of its screening test.
As more drugmakers begin to report…
As more drugmakers begin to report second-quarter earnings against the backdrop of the first material pharmaceutical tariff reveal from the Trump administration, Teva Pharmaceuticals isn’t sweating the situation.
Controversies, including a recent…
Controversies, including a recent regulatory tug-of-war with Sarepta and criticism from conservatives, marked Vinay Prasad's short tenure.
Daré Bioscience has started a…
Daré Bioscience has started a consumer awareness campaign to lay the foundations for the launch of its female sexual arousal drug, rolling out video and interactive content on a women’s health app.
Top F.D.A. Official Resigns Under Pressure
After turning down several new drugs and restricting use of another, Dr. Vinay Prasad drew the ire of the right-wing influencer Laura Loomer and others.
RFK Jr. Announces Plan to Restrict Opioid-Like Kratom Product
Federal officials said a psychoactive ingredient in kratom had been refined and added to supplements that could quickly become addictive.
Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.
In a phase 3 trial, the newest…
In a phase 3 trial, the newest Bruton’s tyrosine kinase (BTK) inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a head-to-head battle against the oldest treatment in the class, AbbVie and
AstraZeneca CEO Pascal Soriot said…
AstraZeneca CEO Pascal Soriot said the company has had many talks with the U.S. government and has proposed price reduction plans for its drugs.
After a first half that saw…
After a first half that saw Publicis Groupe snap up six companies around the world, the advertising giant is continuing its acquisitive streak with its first health-focused buyout of the year.
As part of a trade agreement…
As part of a trade agreement reached Sunday between the U.S. and the European Union, pharmaceutical imports—along with almost all goods entering the U.S. from the bloc—will be subject to a 15% tariff, according to
Novo Nordisk has named Maziar Mike…
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.
Merck has launched a sweeping…
Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said Tuesday in its quarterly report.